[SCHEDULE 13G/A] Sarepta Therapeutics,, Inc. SEC Filing

Rhea-AI Filing Summary

D. E. Shaw & Co., L.P. and founder David E. Shaw filed Amendment No. 1 to Schedule 13G disclosing a passive 5.1 % holding (5,059,912 shares) in Sarepta Therapeutics (SRPT) as of 18 Jul 2025. The stake is spread across three internal vehicles: D. E. Shaw Valence Portfolios (2.78 m shares), D. E. Shaw Oculus Portfolios (1.39 m) and accounts managed by D. E. Shaw Investment Management (0.89 m).

The reporting persons have shared voting power over 5,000,212 shares and shared dispositive power over the full 5,059,912 shares; they possess no sole voting or dispositive authority. The filing is made under Rule 13d-1(b) as an investment adviser and states the shares were not acquired to influence control of the issuer.

This amendment corrects the original 13G by attaching the Joint Filing Agreement dated 25 Jul 2025; no changes to ownership levels or intent are reported.

Positive

• Institutional confidence: D. E. Shaw & Co. reports a 5.1 % position, adding a respected quantitative firm to SRPT’s shareholder roster and potentially enhancing liquidity.

Negative

• Limited new information: The amendment only supplies a missing exhibit; no additional share accumulation or strategic intent is disclosed, reducing the event’s market impact.

Insights

Financial Analyst

TL;DR: Passive 5.1 % stake by D. E. Shaw signals ongoing institutional support but offers limited near-term catalyst.

D. E. Shaw’s 5 %+ position confirms that a sophisticated quantitative manager remains invested in SRPT. Because the filing is on Schedule 13G (not 13D) and expressly denies control intent, it suggests a portfolio allocation rather than an activist play. The amendment merely attaches a missing exhibit, so no incremental buying/selling is implied. While added institutional ownership can improve liquidity and investor perception, the event is informational and unlikely to drive valuation by itself.

Corporate Governance Specialist

TL;DR: Technical amendment; no governance pressure on SRPT expected.

The switch from initial filing to Amendment No. 1 was triggered by a clerical omission (Joint Filing Agreement). With zero sole voting power and a passive 13G designation, D. E. Shaw has not positioned itself to influence board composition or strategy. Accordingly, the disclosure is not impactful from a governance-change standpoint, though it does keep SRPT’s institutional ownership above the 5 % public-reporting threshold.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Sarepta Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

803607100

(CUSIP Number)

07/18/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 803607100

1

Names of Reporting Persons

D. E. Shaw & Co., L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,000,212.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,059,912.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,059,912.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No. 803607100

1

Names of Reporting Persons

David E. Shaw

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,000,212.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,059,912.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,059,912.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Sarepta Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 215 First Street, Suite 415, Cambridge, MA 02142
Item 2.
(a)	Name of person filing: D. E. Shaw & Co., L.P. David E. Shaw
(b)	Address or principal business office or, if none, residence: The business address for each reporting person is: Two Manhattan West 375 Ninth Avenue, 52nd Floor New York, NY 10001
(c)	Citizenship: D. E. Shaw & Co., L.P. is a limited partnership organized under the laws of the state of Delaware. David E. Shaw is a citizen of the United States of America.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 803607100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: D. E. Shaw & Co., L.P.: 5,059,912 shares This is composed of (i) 2,781,337 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 1,391,459 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., and (iii) 887,116 shares under the management of D. E. Shaw Investment Management, L.L.C. David E. Shaw: 5,059,912 shares This is composed of (i) 2,781,337 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 1,391,459 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., and (iii) 887,116 shares under the management of D. E. Shaw Investment Management, L.L.C. David E. Shaw does not own any shares directly. By virtue of David E. Shaw's position as President and sole shareholder of D. E. Shaw & Co., Inc., which is the general partner of D. E. Shaw & Co., L.P., which in turn is the investment adviser of D. E. Shaw Valence Portfolios, L.L.C. and D. E. Shaw Oculus Portfolios, L.L.C. and the managing member of D. E. Shaw Investment Management, L.L.C., and by virtue of David E. Shaw's position as President and sole shareholder of D. E. Shaw & Co. II, Inc., which is the managing member of D. E. Shaw & Co., L.L.C., which in turn is the manager of D. E. Shaw Valence Portfolios, L.L.C. and D. E. Shaw Oculus Portfolios, L.L.C., David E. Shaw may be deemed to have the shared power to vote or direct the vote of 5,000,212 shares, and the shared power to dispose or direct the disposition of 5,059,912 shares, the 5,059,912 shares as described above constituting 5.1% of the outstanding shares and, therefore, David E. Shaw may be deemed to be the beneficial owner of such shares. David E. Shaw disclaims beneficial ownership of such 5,059,912 shares.
(b)	Percent of class: D. E. Shaw & Co., L.P.: 5.1% David E. Shaw: 5.1%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: D. E. Shaw & Co., L.P.: 0 shares David E. Shaw: 0 shares
	(ii) Shared power to vote or to direct the vote: D. E. Shaw & Co., L.P.: 5,000,212 shares David E. Shaw: 5,000,212 shares
	(iii) Sole power to dispose or to direct the disposition of: D. E. Shaw & Co., L.P.: 0 shares David E. Shaw: 0 shares
	(iv) Shared power to dispose or to direct the disposition of: D. E. Shaw & Co., L.P.: 5,059,912 shares David E. Shaw: 5,059,912 shares
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

D. E. Shaw & Co., L.P.

Signature:	/s/ Daniel R. Marcus
Name/Title:	Daniel R. Marcus / Chief Compliance Officer
Date:	07/25/2025

David E. Shaw

Signature:	/s/ Daniel R. Marcus
Name/Title:	Daniel R. Marcus / Attorney-in-Fact for David E. Shaw
Date:	07/25/2025

Comments accompanying signature: This Schedule 13G amendment is being filed solely to include the Joint Filing Agreement, by and among the Reporting Persons, dated July 25, 2025 (Exhibit 2), which was omitted from the initial filing due to a technical issue encountered by our third-party filing service. Exhibit 1: Power of Attorney, granted by David E. Shaw relating to D. E. Shaw & Co., Inc., in favor of the signatories hereto, among others, dated August 1, 2024.

Exhibit Information

Exhibit 2: Joint Filing Agreement, by and among the Reporting Persons, dated July 25, 2025.

FAQ

How many Sarepta Therapeutics (SRPT) shares does D. E. Shaw own?

The filing reports 5,059,912 shares, representing 5.1 % of SRPT’s outstanding common stock.

Is D. E. Shaw seeking control or board influence at SRPT?

No. The Schedule 13G filing is passive and states the shares were not acquired to influence control.

Why was this Schedule 13G/A amendment filed?

It was filed solely to include the Joint Filing Agreement dated 25 Jul 2025 that was inadvertently omitted from the initial filing.

What voting and dispositive powers does D. E. Shaw have over the SRPT shares?

The firm has shared voting power over 5,000,212 shares and shared dispositive power over 5,059,912 shares; it has no sole authority.

Does David E. Shaw personally own SRPT shares?

He holds no shares directly; his reported beneficial ownership is through his control of D. E. Shaw entities.